DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose
monitoring (CGM) for people with diabetes, is presenting important
clinical data for patients with type 1 and type 2 diabetes, at the
American Diabetes Association’s 77th Scientific Sessions, June 9-13
in San Diego, California.
The new data is the result of combined type 1 and type 2 cohorts
from the DIaMonD study (Multiple Daily Injections and Continuous
Glucose Monitoring in Diabetes) and demonstrates the impact of CGM
on A1C, hyperglycemia and hypoglycemia in adults with either type 1
or type 2 diabetes who choose to take multiple daily injections of
insulin in lieu of other methods of insulin delivery. The study
showed DexCom CGM System users achieved a 0.9 percent average A1C
reduction after 24 weeks of regular use, compared to 0.5 percent in
the Usual Care group that relied only on fingerstick blood glucose
measurements. The benefits in glycemic control were seen even in
study participants using CGM that had large decreases in the number
of fingersticks.
Additional highlights include:
- Strong adherence to CGM in adults with
both type 1 and type 2 diabetes regardless of age, education or
numeracy.
- Ninety-three percent were using CGM
more than six days a week in month six.
- Consistent A1C reductions in all
subgroups.
- Time in range increased, while times in
hypoglycemia and hyperglycemia decreased.
- Patients with both type 1 and type 2
diabetes frequently interact with their CGM display device,
providing greater glucose awareness and better informing their
diabetes management decisions.
“This new data represents another important milestone in a
blockbuster year for the advancement of diabetes management,” said
Kevin Sayer, President and CEO of DexCom. “As the first and only
therapeutic CGM approved by Medicare for patients age 65 or older,
DexCom G5 Mobile is setting a new standard of care for a wide
spectrum of patients.”
The study results are being presented during the following
abstract and oral presentations:
First authorPresentation
no.
Title
Date / Time(GPS = General Poster
Session)
Saturday, June 10
Price 65-OR(Price, Riddlesworth, Beck,
Wolpert, Bergenstal, Ahmann)
Effect of Continuous Glucose Monitoring on Glycemic
Control in Adults Using Multiple Daily Insulin Injections
Saturday 6/10 oral presentation
Session “Where is Glucose Monitoring
Taking Us?”Time: 8:00AM to 10:00AM.
Price 928-P(Price, Riddlesworth, Beck)
Glycemic Impact of Reduced Frequency of
Blood Glucose Monitoring with Continuous Glucose Monitoring Use
Saturday 6/10 GPSCat 12A: Clin Ther / New
TechTime: 11:30AM to 12:30PM
Polonsky 926-P
Satisfaction with Continuous Glucose
Monitoring: How Do the Experiences of Insulin-Using Adults with
Type 1 Diabetes vs. Type 2 Diabetes Differ?
Saturday 6/10 GPSCat 12A: Clin Ther / New
TechTime: 11:30AM to 12:30PM
Sunday, June 11
Welsh 97-LB(Welsh, Kelly, Casal,
Walker)
Continuous glucose monitoring-related
behaviors in the DIaMonD randomized controlled trial
Sunday 6/11 GPSCat 11: Psychosocial /
BehavioralTime: Noon to 1:00PM
With the recent U.S. Center for Medicare and Medicaid Services’
approval for coverage of DexCom G5 Mobile, continuous glucose
monitoring is a key area of focus at the American Diabetes
Association’s 77th Scientific Sessions, supported by the following
abstract and oral presentations being conducted by additional
investigators:
- CGM: How do experiences of insulin
using adults with T1D vs T2D differ?
- CGM is safe for making treatment
decisions in T1D: Evidence from in-silico trial
- Use of Remote Digital Monitoring on
Glucose Management Teams in Hospitalized High Risk Patients to
Reduce Hypo- and Hyperglycemia
To learn more about DexCom CGM, visit www.dexcom.com.
Additional Study Information
This clinical study was conducted at 29 clinical sites across
North America using 147 adult subjects with type 1 diabetes on MDI
insulin therapy and 132 adult subjects with type 2 diabetes with a
mean age of 52 years and 57 years for the CGM and Usual Care groups
respectively. The protocol was designed to limit encounters to
allow translation into clinical practice with only one scheduled
encounter after month 1 and none between months 3 and 6. The first
and only randomized, controlled trial focused on CGM for MDI, the
DIaMonD study delivers compelling evidence of significant
improvements across several measures of glycemic control.
About Diabetes and Continuous Glucose Monitoring
With diabetes, the body cannot produce or use the hormone
insulin effectively, causing a buildup of glucose, or sugar, in the
blood. People with diabetes who take insulin must monitor their
blood glucose levels frequently. Uncontrolled glucose can cause
health complications and even death.i,ii
Continuous glucose monitoring (CGM) is considered the most
significant breakthrough in diabetes management in the past 40
years.iii CGM is important because, in addition to providing the
glucose level, it provides the direction and rate of glucose change
with the push of a button and alerts users when glucose is too low
or too high with built-in and customizable alarms. A recent study
showed that after one year, patients with Type 1 diabetes who used
CGM alone had significant A1C reductions regardless of the type of
insulin delivery method used, including insulin pumps.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated
to helping people better manage their diabetes by developing and
marketing continuous glucose monitoring (CGM) products and tools
for adult and pediatric patients. With exceptional performance,
patient comfort and lifestyle flexibility at the heart of its
technology, users have consistently ranked DexCom highest
in customer satisfaction and loyalty. For more information on the
DexCom CGM, visit www.dexcom.com.
References
i Hyperglycemia (High blood glucose). American Diabetes
Association Web site.
http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hyperglycemia.html.
Updated August 5, 2013. Accessed December 3, 2013.ii Hypoglycemia
(Low blood glucose). American Diabetes Association Web site.
http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html.
Updated July 16, 2013. Accessed December 3, 2013.iii Clarke SF and
Foster JR. A history of blood glucose meters and their role in
self-monitoring of diabetes mellitus.Br J Biomed Sci.
2012;(3)2:83-93.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170609005161/en/
for DexCom, Inc.INVESTOR:Steve Pacelli,
858-200-0200orPRESS:Melissa Katz, 215-514-0957
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Apr 2023 to Apr 2024